Peptides on the WADA Prohibited List — a 2026 reference.

For researchers and compliance professionals, understanding which peptides WADA prohibits is operationally critical. The answer is not a simple "is it on the list." The categories, the in-competition vs out-of-competition split, and the detection methods each carry distinct implications. This reference maps the current landscape.

WADA updates the Prohibited List annually. Each version takes effect January 1. The 2026 edition keeps the structure from prior years: S0 captures non-approved substances, S1 covers anabolic agents, S2 covers peptide hormones and growth factors, S3 through S5 cover other categories, and M1 through M3 cover prohibited methods. S6 through S9 are in-competition-only prohibitions (stimulants, narcotics, cannabinoids, glucocorticoids).

For peptides, the practical implication is straightforward. The categories that cover peptides (S0 and S2) are prohibited at all times. Out-of-competition testing can detect them and produce an anti-doping rule violation regardless of when the substance was used. There is no off-season window for these molecules.

What's prohibited under S0?

S0 Non-Approved Substances is the catchall for compounds not approved for human therapeutic use by any government health authority anywhere in the world. The language is broad on purpose: any pharmacological substance that isn't approved by any health authority and isn't covered by another category falls under S0. That's the regulatory hook that catches experimental compounds, research-grade peptides, and any pharmacological agent without formal approval.

BPC-157 is the most prominent peptide explicitly added to S0. WADA added BPC-157 to the Prohibited List effective January 1, 2022, with a specific citation in the explanatory notes. The decision reflected BPC-157's rising prominence in grey-market athletic and rehabilitation contexts plus its lack of regulatory approval anywhere. Any person subject to WADA testing from 2022 onward must treat BPC-157 as unambiguously prohibited.

The breadth of S0 means other research-grade peptides without formal approval can fall under the category even when not named. The analytical interpretation: if a substance is identified in a sample and is not approved for human therapeutic use, it can support an S0 violation whether or not it appears on a named-substance list. Absence from the named list is not a compliance safe harbour.

What's prohibited under S2?

S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics covers most of the GH-axis and tissue-repair peptides athletes encounter. The category breaks into subgroups, and most research-grade work touches one of these:

• S2.1 · Erythropoietin (EPO), EPO mimetics, EPO receptor agonists. Not typically a research-peptide category, but included for completeness.
• S2.2 · Peptide hormones and their releasing factors. This is where most GH-axis peptides sit. Growth hormone itself, growth hormone-releasing hormone (GHRH) and its analogs (sermorelin, tesamorelin, CJC-1295 with or without DAC), growth hormone secretagogues and ghrelin mimetics (ipamorelin, hexarelin, GHRP-2, GHRP-6, MK-677/ibutamoren), plus corticotrophins (ACTH, tetracosactide).
• S2.3 · Growth factors and growth factor modulators. Fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1) and its analogs (IGF-1 LR3, mechano growth factor / MGF), platelet-derived growth factor (PDGF), thymosin-β4 (TB-500 / Tβ4), and vascular endothelial growth factor (VEGF).

Most peptides associated with tissue repair, growth-hormone modulation, or metabolic research fall under S2 and are prohibited at all times. The S2.2 GH-releasing hormones and secretagogues attract the heaviest analytical scrutiny due to historical association with performance enhancement. The S2.3 growth factors (TB-500 in particular) are routinely targeted in accredited laboratory assays as well.

BPC-157

Pentadecapeptide 15 aa Gastric origin

The compound named in WADA’s January 2022 S0 addition. Lab-verified identity and purity for non-athletic research applications.

View BPC-157

In-competition vs out-of-competition

This is the distinction athletes get wrong most often. The WADA Prohibited List has two windows. Substances are either prohibited "at all times" (out-of-competition AND in-competition), or "in-competition only" (defined as the period from 11:59pm the day before competition through the end of competition and sample collection).

Substances prohibited "at all times" include S0, S1 (anabolic agents), S2 (peptide hormones and growth factors), S3 (beta-2 agonists), S4 (hormone and metabolic modulators), and S5 (diuretics and masking agents). All the major peptide categories sit here. No off-season window.

Substances prohibited "in-competition only" include S6 (stimulants), S7 (narcotics), S8 (cannabinoids), and S9 (glucocorticoids). These are the categories where timing relative to competition matters. None of the major peptide categories are in this group.

The practical implication for any tested individual is that peptide use at any point during the year is detectable and can produce a rule violation. Out-of-competition testing can occur at any time during a training period. That scope extends well beyond competition-day testing.

How does WADA testing actually work?

The detection chemistry has come a long way in the last decade. The dominant technique is liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). It separates compounds by their chromatographic behavior and then identifies each one by its mass-to-charge ratio and fragmentation pattern. For peptides, LC-MS/MS can detect picogram-level concentrations of intact peptide in urine and plasma.

The typical protocol: an accredited Doping Control Officer collects urine and/or blood samples. Chain-of-custody transport carries them to a WADA-accredited laboratory. The lab prepares the sample (extraction, enrichment, derivatization where applicable), runs LC-MS/MS against known retention times and fragmentation spectra, and confirms any initial positive with a second analysis. Modern WADA labs can detect dozens of distinct peptides in a single multi-target assay.

Detection windows depend on the specific peptide. Short-half-life peptides (ipamorelin, CJC-1295 without DAC, the drug-affinity-complex modification) can clear from biological samples in hours to a few days, but metabolic breakdown products may persist longer and be detectable themselves. Long-half-life peptides (modified incretins, CJC-1295 with DAC, the long-acting analogs) can be detectable for weeks. Tissue-deposited peptides can show up beyond the plasma clearance window through residual signals in alternative matrices. The athlete assumption that "peptides clear quickly" isn't reliable across the category.

How have categories changed historically?

WADA reviews the Prohibited List annually, and category placement does shift over time. The direction has been expansion rather than contraction. Peptides previously not listed have been added. Analytical scope has broadened. The "related substances and mimetics" clauses in S2 have enabled enforcement against novel compounds without requiring explicit naming.

The most prominent recent change for peptides was the explicit addition of BPC-157 to S0 effective January 2022. Before that, BPC-157 was arguably covered by the general S0 framing (no human therapeutic approval), but the explicit naming removed any ambiguity and signaled WADA's priorities. The TB-500 / thymosin-β4 listing under S2 has been stable across recent updates. The GH-axis peptides (CJC-1295, ipamorelin, hexarelin, GHRP-2, GHRP-6, MK-677) have been on S2 for years and remain there.

The 2026 List doesn't introduce major restructuring for peptide categories. Still, athletes and support personnel should review the annual update each January for specific changes. The structural framing (S0 catchall, S2 peptide hormones and growth factors, both prohibited at all times) is stable for now.

Retatrutide

10 mg ≥99% pure Lyophilized

Triple agonist · GIP/GLP-1/glucagon, 39 aa. An investigational metabolic peptide supplied for non-athletic research use only. COA available with each lot.

Learn more

How do I verify a substance's status?

The authoritative source is WADA's current Prohibited List, published annually at wada-ama.org. Most national anti-doping organizations also publish their own searchable databases that map the WADA categories to specific substance names. The United States Anti-Doping Agency (USADA) Global DRO tool is the most commonly cited example. Similar resources exist in most jurisdictions: UK Anti-Doping, the Australian Sports Anti-Doping Authority, and others.

The standard compliance workflow: identify the substance by chemical name and common synonyms. Search the current Prohibited List for explicit listing. If not explicitly listed, evaluate whether it falls under one of the catchall framings (S0 for non-approved substances, S2 for related substances and mimetics). When ambiguity exists, the appropriate step is to contact the relevant national anti-doping organization directly rather than rely on general inference. A missed compliance check can result in an anti-doping rule violation with significant competitive consequences.

What about Therapeutic Use Exemptions (TUEs)?

WADA allows athletes to use certain prohibited substances therapeutically if the substance is medically necessary, has no acceptable non-prohibited alternative, and is not performance-enhancing beyond the therapeutic effect. The Therapeutic Use Exemption (TUE) process is the formal pathway. TUEs are granted by the relevant national anti-doping organization or international federation after medical review. Documentation requirements are extensive.

For peptides specifically, TUEs are uncommon. Most molecules in S0 and S2 do not have established human therapeutic indications that satisfy the "no acceptable alternative" criterion. Growth hormone TUEs for documented adult GH deficiency exist but are subject to careful review. TUEs for research-grade peptides without any therapeutic approval (BPC-157, TB-500 in most jurisdictions) are essentially never granted because no validated therapeutic indication exists to support the exemption.

Key questions for a compliance review

When a support team or compliance officer is reviewing a specific compound, the following questions represent the standard framework:

• Is the substance explicitly named on the current WADA Prohibited List? The annual update is the primary reference. Prior-year status does not guarantee current status.
• If not explicitly named, does it fall under a catchall (S0, S2 related substances and mimetics)? Those framings capture many compounds without explicit listing.
• Prohibited at all times, or only in-competition? Almost all peptide categories are at-all-times prohibitions. Verification is warranted before assuming an off-season window exists.
• What is the detection window for the substance? The answer depends on pharmacokinetics. The assumption that peptides clear quickly is not reliable across the category.
• Could a TUE be granted for documented therapeutic need? TUEs are rare for research-grade peptides. Review with the relevant national anti-doping organization before any therapeutic decision.